GRP 75 Lentiviral Activation Particles (h): sc-400471-LAC

HSPA9 encodes GRP75 (mortalin), a mitochondria-associated HSP70 chaperone that supports protein import, folding, and proteostasis within the mitochondrial matrix and at mitochondria–ER contact sites. GRP75 contributes to mitochondrial biogenesis and quality control, integrates stress responses with energy metabolism, and modulates apoptosis and senescence through interactions with pathways such as p53 signaling and oxidative stress networks. Altered HSPA9/GRP75 function has been linked to mitochondrial dysfunction phenotypes and is studied in contexts including neurodegeneration, hematopoietic failure syndromes, and cancer cell metabolism. As a central regulator of cellular stress resilience, GRP75 is frequently investigated for its roles in mitochondrial dynamics, reactive oxygen species handling, and mitochondrial-associated membrane signaling.

GRP 75 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient HSPA9 upregulation across a broader range of human cell types.

GRP 75 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the HSPA9 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous GRP 75 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native HSPA9 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.